Brolucizumab

Beovu 120 MG/ML Solucion Inyectable en Jeringa Precargada

19,8 mg solución inyectable en jeringa precargadaSpainMarketedAuthorised 27 Feb 2020

In other countries

The same active substances on other registers, the same brand first.

BeovuCanada · 6 MG / 0.05 ML · Solution · Novartis Pharmaceuticals Canada INCSame brand
BeovuCanada · 6 MG / 0.05 ML · Solution · Novartis Pharmaceuticals Canada INCSame brand
BeovuEuropean Union · Novartis Europharm LimitedSame brand
BeovuCroatiaSame brand
BeovuItaly · Soluzione iniettabile · Novartis Europharm LimitedSame brand
Beovu 120 mg/ml, oplossing voor injectieNetherlands · Oplossing voor injectie · Novartis Europharm LimitedSame brand
BEOVU 120mg/mlRomania · 120mg/ml · sol. inj. in seringa preumpluta · Novartis Europharm LimitedSame brand

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Brolucizumab

Beovu 120 MG/ML Solucion Inyectable en Jeringa Precargada

19,8 mg solución inyectable en jeringa precargadaSpainMarketedAuthorised 27 Feb 2020

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Beovu®Serbia · 120mg/mL · rastvor za injekciju · PredstavniŠTvo Novartis Pharma Services INC. Beograd (Novi Beograd)

BeovuSaudi Arabia · NOVARTIS Pharma Stein AG

BeovuSaudi Arabia · Alcon Couvreur

BeovuUnited States · 6MG/0.05ML · injectable · Novartis Pharms Corp

BeovuUnited States · 6MG/0.05ML · Injection · Novartis Pharmaceuticals Corporation

VsiqqBrazil · Novartis Biociencias S.A

VsiqqBrazil · Sandoz do Brasil Indústria Farmacêutica Ltda

Packs

Pack	Code	Status
BEOVU 120 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA, 1 jeringa precargada de 0,165 ml	728099

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Brolucizumab
Strength: 19,8 mg
Dosage form: solución inyectable en jeringa precargada
Route: vía intravítrea
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 27 Feb 2020
Registration: 1191417
Marketing authorisation holder: Novartis Europharm Limited
Procedure: EU centralised
Supply: Uso Hospitalario